FBRX earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -12.36. Updated 2026-07-23.
Forte Biosciences (FBRX) Research Hub
Forte Biosciences (FBRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-08-28, shares last closed at 76.99 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -12.36, market cap 0.70B. This hub links to the full technical, earnings and options research available for FBRX.
Last updated 2026-08-28 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 76.99 USD (0.00%) |
| 52-week range | 17.17 USD – 77.2 USD |
| Trend regime | Range |
| 14-day RSI | 61.2 (Bullish) |
| Trailing P/E | -12.36 |
| Market cap | 0.70B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for FBRX
Covered Call on FBRX: how it works, illustrative setup around the real 76.99 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on FBRX: how it works, illustrative setup around the real 76.99 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on FBRX: how it works, illustrative setup around the real 76.99 USD price, max profit/loss, breakeven and when to use it. Educational.
FBRX technical analysis: range, last 76.99 USD, RSI 61.2, 52w range 17.17 USD–77.2 USD, real support/resistance. Updated 2026-08-28.
Frequently asked questions
What sector is FBRX in?
Forte Biosciences (FBRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is FBRX in an uptrend or downtrend?
As of 2026-08-28, FBRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is FBRX's trailing P/E ratio?
FBRX's trailing P/E is -12.36, with a market cap of 0.70B. See the earnings research page for full valuation detail.
When does FBRX next report earnings?
FBRX is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.9248 USD.